This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss
For any queries, please contact Customer Services or your Account Manager. Dismiss
News & Analysis (1207)
-
December 12, 2025 | Insight Edwards-JenaValve deal better for patients, companies argue in post-trial brief
Sections: DealRisk® and Mergers and Acquisitions
-
December 11, 2025 | Comment Third-party testimony could turn tide in US FTC’s challenge of Edwards-JenaValve
...and Drug Administration approval process, but their testing requirements depend on the locale and are...
Sections: DealRisk® and Mergers and Acquisitions
-
December 10, 2025 | Official Statement Teva removes over 200 improper patent listings under pressure from US FTC
...MLex Summary: Teva Pharmaceuticals has requested that the US Food and Drug Administration remove more...
Sections: Antitrust
Get the inside track, with MLex
With a global network of expert journalists digging deep into the areas of risk that matter to your business and clients—and the highest standards of impartiality—you can have complete trust in MLex to keep you ahead of the regulatory curve.
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from specialists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
TRY MLEX FREE FOR 14 DAYS
View full search results
Already a subscriber? Click here to login